GLPwatch

Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice.

Vnitr Lek · 2022

Last updated 2026-05-28

Oral semaglutide (Rybelsus®) is a GLP-1 drug taken by mouth, used to treat type 2 diabetes. In a trial called PIONEER 6, it showed no increased risk of cardiovascular problems and was linked to lower rates of cardiovascular and overall death. It also helps with blood sugar control and weight loss with minimal risk of low blood sugar.

AI summary of the abstract below.

JournalVnitr Lek, 2022
Citations3
Relative citation ratio0.29
NIH percentile18
Molecules semaglutide
Conditions studied Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction

Abstract

Glucagon like peptide-1 receptor agonists (GLP-1 RA) are potent antidiabetic drugs associated with significant weight loss and minimal risk of hypoglycemia. Semaglutide is a GLP-1 RA with a proven cardiovascular benefit. It is currently also available in oral form, which is especially suitable for the treatment of the initial phase of type 2 diabetes. However, it is also effective at later initiation of therapy, in different diabetic populations. The PIONEER 6 trial demonstrated cardiovascular safety of oral semaglutide, its administration was accompanied by a significant reduction in cardiovascular and overall mortality.

Verbatim abstract via PubMed 36208922 ↗

Related research